Skip to main content
. 2017 Dec 28;17:216. doi: 10.1186/s12890-017-0563-7

Table 2.

PAH-targeted therapy received prior to switching to riociguat

Therapy, n (%) Full analysis set
(n = 300)
Any prior therapy 84 (28)
Endothelin receptor antagonists 44 (15)
 Ambrisentan 8 (3)
 Bosentan 36 (12)
PDE5 inhibitors 58 (19)
 Sildenafil 42 (14)
 Tadalafil 16 (5)
Prostacyclins and prostacyclin analogues 7 (2)
 Beraprost 1 (<1)
 Iloprost 6 (2)
Combination therapy 24 (8)
 Double therapy 23 (8)
 Triple therapy 1 (<1)

PAH pulmonary arterial hypertension, PDE5 phosphodiesterase type 5